Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis

NCT00537082 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00537082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00537082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study Comparing Efficacy and Safety of FTY720 0.5 mg and 1.25 mg Administered Orally Once Daily in Patients With Relapsing Multiple Sclerosis
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
Not reported
Enrollment
171 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis